Agmatine Reverses Sub-chronic Stress induced Nod-like Receptor Protein 3 (NLRP3) Activation and Cytokine Response in Rats

Basic and Clinical Pharmacology and Toxicology

Volumn 119, Issue 4, 2016, Pages 367-375

  Sahin, Ceren ^a   Albayrak, Ozgur ^b   Akdeniz, Tuğba F ^b   Akbulut, Zeynep ^b   Yanikkaya Demirel, Gulderen ^b   Aricioglu, Feyza ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b YEDITEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

A 7127; AGMATINE; ANTIDEPRESSANT AGENT; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; NOD LIKE RECEPTOR PROTEIN 3; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BRAIN REGION; CHRONIC STRESS; CONTROLLED STUDY; CYTOKINE RESPONSE; DOWN REGULATION; DRUG INHIBITION; GENE EXPRESSION; HIPPOCAMPUS; MALE; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

EID: 84987814966     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12604     Document Type: Article

References (70)

1. Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression and systemic illnesses. Brain Behav Immun 2013;31:105–14.
2. Jones KA, Thomsen C. The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci 2013;53:52–62.
3. Madrigal JL, Hurtado O, Moro MA, Lizasoain I, Lorenzo P, Castrillo A et al. The increase in TNF-alpha levels is implicated in NF-kappaB activation and inducible nitric oxide synthase expression in brain cortex after immobilization stress. Neuropsychopharmacology 2002;26:155–63.
4. Nguyen KT, Deak T, Will MJ, Hansen MK, Hunsaker BN, Fleshner M et al. Timecourse and corticosterone sensitivity of the brain, pituitary, and serum interleukin-1beta protein response to acute stress. Brain Res 2000;859:193–201.
5. O'Connor KA, Johnson JD, Hansen MK, Frank JLW, Maksimova E, Watkins LR et al. Peripheral and central proinflammatory cytokine response to a severe acute stressor. Brain Res 2003;991:123–32.
6. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006;27:24–31.
7. Koo JW, Duman RS. IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 2008;105:751–6.
8. Koo JW, Duman RS. Evidence for IL-1 receptor blockade as a therapeutic strategy for the treatment of depression. Curr Opin Investig Drugs 2009;10:664–71.
9. Hannestad J, DellaGioia N, Bloch M. The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis. Neuropsychopharmacology 2011;36:2452–9.
10. Ferrero-Miliani F, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1β generation. Clin Exp Immunol 2007;147:227–35.
11. Ogura Y, Sutterwala FS, Flavell RA. The inflammasome: first line of the immune response to cell stress. Cell 2006;126:659–62.
12. Petrilli V, Papin S, Tschopp J. The inflammasome. Curr Biol 2005;15:581.
13. Alcocer-Gómez E, de Miguel M, Casas-Barquero N, Núñez-Vasco J, Sánchez-Alcazar JA, Fernández-Rodríguez A et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun 2014;36:111–7.
14. Pan Y, Chen XY, Zhang QY, Kong LD. Microglial NLRP3 inflammasome activation mediates IL-1b-related inflammation in prefrontal cortex of depressive rats. Brain Behav Immun 2014;41:90–100.
15. Zhang Y, Liu L, Liu YZ, Shen XL, Wu TY, Zhang T et al. NLRP3 inflammasome mediates chronic mild stress-induced depression in mice via neuroinflammation. Int J Neuropsychopharmacol 2015;18:1–8.
16. Zhang Y, Liu L, Peng YL, Liu YZ, Wu TY, Shen XL et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS Neurosci Ther 2014;20:1119–24.
17. Chakraborty S, Kaushik DK, Gupta M, Basu A. Inflammasome signaling at the heart of central nervous system pathology. J Neurosci Res 2010;88:1615–31.
18. Vladimer GI, Marty-Roix R, Ghosh S, Weng D, Lien E. Inflammasome and host defenses against bacterial infections. Curr Opin Microbiol 2013;16:23–31.
19. Pelegrin P, Surprenant A. Pannexin-1 mediates large pore formation and interleukin-1beta release by the ATP-gated P2X7 receptor. EMBO J 2006;25:5071–82.
20. Pelegrin P, Surprenant A. Pannexin-1 couples to maitotoxin and nigericin-induced interleukin-1beta release through a dye uptake-independent pathway. J Biol Chem 2007;282:2386–94.
21. Stehlik C, Dorfleutner A. COPs and POPs: modulators of inflammasome activity. J Immunol 2007;179:7993–8.
22. Haneklaus M, O'Neill LA, Coll RC. Modulatory mechanisms controlling the NLRP3 inflammasome in inflammation: recent developments. Curr Opin Immunol 2013;25:40–5.
23. Piletz JE, Aricioglu F, Cheng JT, Fairbanks CA, Gilad VH, Haenisch BA et al. Agmatine: clinical applications after 100 years in translation. Drug Discov Today 2013;18:880–93.
24. Raasch W, Regunathan S, Li G, Reis DJ. Agmatine, the bacterial amine, is widely distributed in mammalian tissues. Life Sci 1995;56:2319–30.
25. Reis DJ, Regunathan S. Agmatine: an endogenous ligand at imidazoline receptors is a novel neurotransmitter. Ann N Y Acad Sci 1999;881:65–80.
26. Reis DJ, Regunathan S. Is agmatine a novel neurotransmitter in brain? Trends Pharmacol Sci 2000;21:187–93.
27. Auguet M, Viossat I, Marin JG, Chabrier PE. Selective inhibition of inducible nitric oxide synthase by agmatine. Jpn J Pharmacol 1995;69:285–7.
28. Mun CH, Lee WT, Park KA, Lee JE. Regulation of endothelial nitric oxide synthase by agmatine after transient global cerebral ischemia in rat brain. Anat Cell Biol 2010;43:230–40.
29. Loring RH. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br J Pharmacol 1990;99:207–11.
30. Halaris A, Plietz J. Agmatine: metabolic pathway and spectrum of activity in brain. CNS Drugs 2007;21:885–900.
31. Aricioglu F, Korcegez E, Bozkurt A, Ozyalcin S. Effect of agmatine on acute and mononeuropathic pain. Ann N Y Acad Sci 2003;1009:106–15.
32. Santos ARS, Gadotti VM, Oliveira GL, Tibola D, Paszcuk AF, Neto A et al. Mechanisms involved in the antinociception caused by agmatine in mice. Neuropharmacology 2005;48:1021–34.
33. Aricioglu F, Altunbas H. Is agmatine an endogenous anxiolytic/antidepressant agent? Ann N Y Acad Sci 2003;1009:136–40.
34. Aricioglu F, Kan B, Korcegez E, Berkman K. Effect of agmatine on electrically and chemically induced seizures in mice. Ann N Y Acad Sci 2003;1009:141–6.
35. Luszczki JJ, Czernecki R, Wojtal K, Borowicz KK, Czuczwar SJ. Agmatine enhances the anticonvulsant action of phenobarbital and valproate in the mouse maximal electroshock seizure model. J Neural Transm 2008;115:1485–94.
36. Aricioglu-Kartal F, Uzbay IT. Inhibitory effect of agmatine on naloxone precipitated abstinence syndrome in morphine dependent rats. Life Sci 1997;61:1775–81.
37. Aricioglu-Kartal F, Regunathan S. Effect of chronic morphine treatment on the biosynthesis of agmatine in rat brain and other tissues. Life Sci 2002;71:1695–701.
38. Aricioglu F, Means A, Regunathan S. Effect of agmatine on the development of morphine dependence in rats: potential role of cAMP system. Eur J Pharmacol 2004;504:191–7.
39. Aricioglu F. Paul IA, Regunathan S. Agmatine reduces only peripheral-related behavioral signs, not the central signs, of morphine withdrawal in nNOS deficient transgenic mice. Neurosci Lett 2004;354:153–7.
40. Gilad GM, Salame K, Rabey JM, Gilad VH. Agmatine treatment is neuroprotective in rodent brain injury models. Life Sci 1996;58:41–6.
41. Gilad GM, Gilad VH. Accelerated functional recovery and neuroprotection by agmatine after spinal cord ischemia in rats. Neurosci Lett 2000;296:97–100.
42. Wag WP, Iyo AH, Miguel-Hidalgo J, Regunathan S, Zhu MY. Agmatine protects against cell damage induced by NMDA and glutamate in cultured hippocampal neurons. Brain Res 2006;1084:210–6.
43. Utkan T, Gocmez SS, Regunathan S, Aricioglu F. Agmatine, a metabolite L-arginine, reverses scopolamine-induced learning and memory impairment in rats. Pharmacol Biochem Behav 2012;102:578–84.
44. Gumru S, Sahin C, Aricioglu F. Role of agmatine in cognitive functions. OA Behav Med 2013;1:2.
45. Aricioglu F, Regunathan S, Piletz JE. Is agmatine an endogenous factor against stress? Ann N Y Acad Sci 2003;1009:127–32.
46. Aricioglu F, Regunathan S. Agmatine attenuates stress- and lipopolysaccharide-induced fever in rats. Physiol Behav 2005;85:370–5.
47. Regunathan S, Feinstein DL, Reis DJ. Anti-proliferative and anti-inflammatory actions of imidazoline agents. Are imidazoline receptors involved? Ann N Y Acad Sci 1999;881:410–9.
48. Regunathan S, Piletz JE. Regulation of inducible nitric oxide synthase and agmatine synthesis in macrophages and astrocytes. Ann N Y Acad Sci 2003;1009:20–9.
49. Paszcuk AF, Gadotti VM, Tibola D, Quintão NL, Rodrigues AL, Calixto JB et al. Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice. Brain Res 2007;1159:124–33.
50. Neis VB, Manosso LM, Moretti M, Freitas AE, Daufenbach J, Rodrigues AL. Depressive-like behavior induced by tumor necrosis factor-α is abolished by agmatine administration. Behav Brain Res 2014;261:336–44.
51. Ishikawa I, Kitamura H, Kimura K, Saito M. Brain interleukin-1 is involved in blood interleukin-6 response to immobilization stress in rats. Jpn J Vet Res 2001;49:19–25.
52. Zhou D, Kusnecov AW, Shurin MR, DePaoli M, Rabin BS. Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis. Endocrinology 1993;133:2523–30.
53. Liu B, Xu C, Wu X, Liu F, Du Y, Sun J et al. Icariin exerts an antidepressant effect in an unpredictable chronic mild stress model of depression in rats and is associated with the regulation of hippocampal neuroinflammation. Neuroscience 2015;294:193–205.
54. Li R, Wang X, Qin T, Qu R, Ma S. Apigenin ameliorates chronic mild stress-induced depressive behavior by inhibiting interleukin-1β production and NLRP3 inflammasome activation in the rat brain. Behav Brain Res 2015;296:318–25.
55. Alcocer-Gómez E, Ulecia-Morón C, Marín-Aguilar F, Rybkina T, Casas-Barquero N, Ruiz-Cabello J et al. Stress-induced depressive behaviors require a functional NLRP3 inflammasome. Mol Neurobiol 2015;52:1–9.
56. Xue J, Li H, Deng X, Ma Z, Fu Q, Ma S. L-Menthone confers antidepressant-like effects in an unpredictable chronic mild stress mouse model via NLRP3 inflammasome-mediated inflammatory cytokines and central neurotransmitters. Pharmacol Biochem Behav 2015;134:42–8.
57. Deng XY, Li HY, Chen JJ, Li RP, Qu R, Fu Q et al. Thymol produces an antidepressant-like effect in a chronic unpredictable mild stress model of depression in mice. Behav Brain Res 2015;291:12–9.
58. Deng XY, Xue JS, Li HY, Ma ZQ, Fu Q, Qu R et al. Geraniol produces antidepressant-like effects in a chronic unpredictable mild stress mice model. Physiol Behav 2015;152:264–71.
59. Myint AM, Leonard BE, Steinbusch HW, Kim YK. Th1, Th2, and Th3 cytokine alterations in major depression. J Affect Disord 2005;88:167–73.
60. Song C, Halbreich U, Han C, Leonard BE, Luo H. Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry 2009;42:182–8.
61. Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol 2007;76396:1–6.
62. You Z, Luo C, Zhang W, Chen Y, He J, Zhao Q et al. Pro- and anti-inflammatory cytokines expression in rat's brain and spleen exposed to chronic mild stress: involvement in depression. Behav Brain Res 2011;225:135–41.
63. Freitas AE, Bettio LE, Neis VB, Santos DB, Ribeiro CM, Rosa PB et al. Agmatine abolishes restraint stress-induced depressive-like behavior and hippocampal antioxidant imbalance in mice. Prog Neuropsychopharmacol Biol Psychiatry 2014;50:143–50.
64. Song J, Kumar BK, Kang S, Park KA, Lee WT, Lee JE. The effect of agmatine on expression of IL-1β and TLX which promotes neuronal differentiation in lipopolysaccharide-treated neural progenitors. Exp Neurobiol 2013;22:268–76.
65. Taksande BG, Chopde CT, Umekar MJ, Kotagale NR. Agmatine attenuates lipopolysaccharide induced anorexia and sickness behavior in rats. Pharmacol Biochem Behav 2015;132:108–14.
66. Satriano J, Schwartz D, Ishizuka S, Lortie MJ, Thomson SC, Gabbai F et al. Suppression of inducible nitric oxide generation by agmatine aldehyde: beneficial effects in sepsis. J Cell Physiol 2001;18:313–20.
67. Li X, Liu Z, Jin H, Fan X, Yang X, Tang W et al. Agmatine protects against zymosan-induced acute lung injury in mice by inhibiting NF-κB-mediated inflammatory response. Biomed Res Int 2014;583736:1–10.
68. Freitas AE, Egea J, Buendía I, Navarro E, Rada P, Cuadrado A et al. Agmatine induces Nrf2 and protects against corticosterone effects in hippocampal neuronal cell line. Mol Neurobiol 2015;51:1504–19.
69. Freitas AE, Egea J, Buendia I, Gómez-Rangel V, Parada E, Navarro E et al. Agmatine, by improving neuroplasticity markers and inducing Nrf2, prevents corticosterone-induced depressive-like behavior in mice. Mol Neurobiol 2015;51:1–15.
70. Lavinsky D, Arteni NS, Netto CA. Agmatine induces anxiolysis in the elevated plus maze task in adult rats. Behav Brain Res 2003;141:19–24.